Canadian guidelines for the management of acute exacerbation of chronic bronchitis: Executive summary

Canadian Respiratory Journal

Volumn 10, Issue 5, 2003, Pages 248-258

  Balter, Meyer S ^a   La Forge, Jacques ^b   Low, Donald E ^a,c   Mandell, Lionel ^d   Grossman, Ronald F ^a   Anzueto, Antonio ^e   Born, Abraham ^a   Bouchard, Jacques ^f   Duguid, Nigel J D ^g   Harding, Godfrey ^h   Julien, Marcel ⁱ   Lampron, Noel ^b   Levy, Robert D ^j   McSherry, James A ^k   Weiss, Karl A ^l  

^a UNIVERSITY OF TORONTO   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^f ST JOSEPH S HOSPITAL   (Canada)

^g MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^h UNIVERSITY OF MANITOBA   (Canada)

ⁱ HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^j UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^k UNIVERSITY OF WESTERN ONTARIO   (Canada)

^l MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHYLLINE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; ANTITUSSIVE AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; BRONCHODILATING AGENT; BUDESONIDE; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIPROFLOXACIN; CLARITHROMYCIN; CORTICOSTEROID DERIVATIVE; COTRIMOXAZOLE; DOXYCYCLINE; EXPECTORANT AGENT; MACROLIDE; METHYLPREDNISOLONE; MUCOLYTIC AGENT; OFLOXACIN; OXYTETRACYCLINE; PREDNISOLONE; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BREATHING EXERCISE; BRONCHODILATING ACTIVITY; CANADA; CHRONIC BRONCHITIS; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; FORCED EXPIRATORY VOLUME; HUMAN; HYPERGLYCEMIA; LUNG FUNCTION TEST; METERED DOSE INHALER; PHYSIOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SPUTUM ANALYSIS; THORAX RADIOGRAPHY;

EID: 0141558911     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2003/108656     Document Type: Review

References (135)

1. Balter M, Hyland R, Low D. Recommendations on the management of chronic bronchitis: A practical guide for Canadian physicians. Can Med Assoc J 1994; 151 (Suppl):7-33.
2. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis 2000;31:383-421.
3. Lung Facts. Ottawa: Canadian Lung Association, 1991.
4. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995;8:1398,420.
5. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152:S77-121.
6. Definition and classification of chronic bronchitis for clinical and epidemiological purposes. A report to the Medical Research Council by their Committee on the Aetiology of Chronic Bronchitis. Lancet 1965;1:775-9.
7. Oswald NC, Harold JT, Martin WJ. Clinical pattern of chronic bronchitis. Lancet 1953;2:693-743.
8. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.
9. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608-13.
10. Haas H, Morris J, Samson S, Kilbourn J, Kim P. Bacterial flora of the respiratory tract in chronic bronchitis: Comparison of transtracheal, fiberbronchoscopic, and oropharyngeal sampling methods. Am Rev Respir Dis 1977;116:41-7.
11. Hager H, Verghese A, Alvarez S, Berk S. Branhamella catarrhalis respiratory infections. Rev Infect Dis 1987;9:1140-9.
12. Tager I, Speizer F. Role of infection in chronic bronchitis. N Engl J Med 1975;292:563-71.
13. Vishwanath S, Ramphal R. Adherence of Pseudomonas aeruginosa to human tracheobronchial mucin. Infect Immun 1984;45:197-202.
14. Cole P, Wilson R. Host-microbial interrelationships in respiratory infection. Chest 1989;95:217S-21S.
15. Murphy T, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Respir Dis 1992;146:1067-83.
16. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-22.
17. Mushlin AI, Black ER, Connolly CA, Buonaccorso KM, Eberly SW. The necessary length of hospital stay for chronic pulmonary disease. JAMA 1991;266:80-3.
18. Connors AF, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996;154:959-67.
19. Burk RH, George RB. Acute respiratory failure in chronic obstructive pulmonary disease. Immediate and long-term prognosis. Arch Intern Med 1973;132:865-8.
20. Seneff MG, Wagner DF, Wagner RP, Zimmerman JE, Knaus WA. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA 1995;274:1852-7.
21. Cydulka RK, McFadden ER Jr, Emerman CL, Sivinski LD, Pisanelli W, Rimm AA. Patterns of hospitalization in elderly patients with asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 156:1807-12.
22. Osman IM, Godden DJ, Friend JA, Legge JS, Douglas JG. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax 1997;52:67-71.
23. Peach H, Pathy MS. Follow-up study of disability among elderly patients discharged from hospital with exacerbations of chronic bronchitis. Thorax 1981;36:585-9.
24. Hagedorn SD. Acute exacerbations of COPD. How to evaluate severity and treat the underlying cause. Postgrad Med 1992;91:105-7.
25. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:1618-23.
26. Sherman S, Skoney JA, Ravikrishnan KP. Routine chest radiographs in exacerbations of chronic obstructive pulmonary disease. Diagnostic value. Arch Intern Med 1989;149:2493-6.
27. Wolkove N, Dajczman E, Colacone A, Kreisman H. The relationship between pulmonary function and dyspnea in obstructive lung disease. Chest 1989;96:1247-51.
28. Peto R, Speizer F, Cochrane A, et al. The relevance in adults of air-flow obstruction but not of mucus hypersecretion, to mortality from chronic lung disease. Results from 20 years of prospective observation. Am Rev Respir Dis 1983;128:491-500.
29. Hodgkin JE. Prognosis in chronic obstructive pulmonary disease. Clin Chest Med 1990;11:555-69.
30. Vitacca M, Clini E, Porta R, Foglio K, Ambrosino N. Acute exacerbations in patients with COPD: Predictors of need for mechanical ventilation. Eur Respir J 1996;9:1487-93.
31. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial. Br Med J 2000;320:1297-303.
32. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 1998;351:773-80.
33. 1 to clinical outcomes during exacerbations of chronic obstuctive pulmonary disease. The Department of Veterans Affairs Cooperative Study Group. Am J Respir Crit Care Med 2000;161:1201-5.
34. Allegra L, Blasi F, deBernardi B, Cosentini R, Tarsia F. Antibiotic treatment and baseline severity of disease in acute exacerbations of chronic bronchitis: A re-evaluation of previously published data of a placebo controlled randomized study. Pulm Pharmacol Ther 2001;14:149-55.
35. Mannino DM, Etzel RA, Flanders WD. Do the medical history and physical examination predict low lung function? Arch Intern Med 1993;153:1892-7.
36. Kesten S, Chapman K. Physician perceptions and management of COPD. Chest 1993;104:254-8.
37. Renwick DS, Connolly MJ. Prevalence and treatment of chronic airways obstruction in adults over the age of 45. Thorax 1996;51:164-8.
38. Kuhl DA, Agiri OA, Mauro LS. Beta-agonists in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Ann Pharmacother 1994;28:1379-88.
39. Emerman CL, Cydulka RK. Effect of different albuterol dosing regimens in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med 1997;29:474-8.
40. O'Driscoll BR, Taylor RJ, Horsley MG, Chambers DK, Bernstein A. Nebulised salbutamol with and without ipratropium bromide in acute airflow obstruction. Lancet 1989;i:1418-20.
41. Backman R, Helstrom P. Fenoterol and ipratropium bromide for treatment of patients with chronic bronchitis. Curr Ther Res 1985;38:135-40.
42. Karpel JP, Pesin J, Greenberg D, Gentry E. A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD. Chest 1990;98:835-9.
43. Turner M, Patel A, Ginsburg S, FitzGerald J. Bronchodilator delivery in acute airflow obstruction. A meta-analysis. Arch Intern Med 1997;157:1736-44.
44. Rice KL, Leatherman JW, Duane PG, et al. Aminophylline for acute exacerbations of chronic obstructive pulmonary disease. A controlled trial. Ann Intern Med 1987;107:305-9.
45. Seidenfeld JJ, Jones WN, Moss RE, Tremper J. Intravenous aminophylline in the treatment of acute bronchospastic exacerbations of chronic obstructive pulmonary disease. Ann Emerg Med 1984;13:248-52.
46. Schmidt GA, Hall JB. Acute or chronic respiratory failure. Assessment and management of patients with COPD in the emergency setting. JAMA 1989;261:3444-53.
47. Bone R, Pierce A, Johnson RJ. Controlled oxygen administration in acute respiratory failure in chronic obstructive pulmonary disease: A reappraisal. Am J Med 1978;65:896-902.
48. Rosen RL. Acute respiratory failure and chronic obstructive lung disease. Med Clin North Am 1986;70:895-907.
49. Derenne JP, Fleury B, Pariente R. Acute respiratory failure of chronic obstructive pulmonary disease. Am Rev Respir Dis 1988;138:1006-33.
50. Weinberger SE, Schwartzstein RM, Weiss JW. Hypercapnia. N Engl J Med 1989;321:1223-31.
51. Stradling JR. Hypercapnia during oxygen therapy in airways obstruction: A reappraisal. Thorax 1986;41:897-902.
52. Levi-Valensi P. Weitzenblum E, Pedinielli JL, Racineux JL, Duwoos H. Three-month follow-up of arterial blood gas determinations in candidates for long-term oxygen therapy. A multicentric study. Am Rev Respir Dis 1986;133:547-51.
53. European Society of Pneumology Task Group. Recommendations for long term oxygen therapy (LTOT). Eur Respir J 1992;2:160-4.
54. Timms RM, Kvale PA, Anthonisen NR, et al. Selection of patients with chronic obstructive pulmonary disease for long-term oxygen therapy. JAMA 1981;245:2514-5.
55. Finiguerra M, Conti F, Figura I, Legnani W, Morandini G. Clinical study on an antibiotic and mucolytic association (amoxicillin and domiodal) in gypersecretory chronic bronchopulmonary diseases. Curr Ther Res 1982;31:895-905.
56. Langlands JH. Double-blind clinical trial of bromhexine as a mucolytic drug in chronic bronchitis. Lancet 1970;i:448-50.
57. Aylward M. A between-patient, double-blind comparison of S-carboxymethylcysteine and bromhexine in chronic obstructive bronchitis. Curr Med Res Opin 1973;1:219-27.
58. Anthonisen P, Riis P. Sogaard-Anderson T. The value of lung physiotheraphy in the treatment of acute exacerbations in chronic bronchitis. Acta Med Scand 1964;175:715-9.
59. Newton DA, Bevans HG. Physiotherapy and intermittent positive-pressure ventilation of chronic bronchitis. BMJ 1978;ii:1525-8.
60. 1 in chronic bronchitis. Med J Aust 1975;1:33-5.
61. Connors AF, Hammon WE, Martin RJ, Rogers RM. Chest physical therapy. The immediate effect on oxygenation in acutely ill patients. Chest 1980;78:559-64.
62. Plant PK, Owen JL, Elliott MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: A multicentre randomised controlled trial. Lancet 2000;355:1931-5.
63. Keenan SP, Kernerman PD, Cook DJ, Martin CM, McCormack D, Sibbald WJ. Effect of noninvasive positive pressure ventilation on mortality in patients admitted with acute respiratory failure: A meta-analysis. Crit Care Med 1997;25:1685-92.
64. Mehta S, Hill NS. Noninvasive ventilation. Am J Respir Crit Care Med 2001;163:540-77.
65. Emerman C, Connors A, Lukens T, May M, Effron D. A randomized controlled trial of methylprednisolone in the emergency treatment of acute exacerbations of COPD. Chest 1989;95:563-7.
66. Thompson W, Nielson C, Carvalho P, Charan N, Crowley J. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996;154:407-12.
67. Davies L, Angus R, Calverley P. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: A prospective randomised controlled trial. Lancet 1999;354:456-60.
68. Niewoehner D, Erbland M, Deupree R, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999;340:1941-7.
69. Murata G, Gorby M, Chick T, Halperin A. Intravenous and oral corticosteroids for the prevention of relapse after treatment for decompensated COPD: Effect on patients with a history of multiple relapses. Chest 1990;98:845-9.
70. Sayiner A, Aytemur ZA, Cirit M, Unsal I. Systemic glucocorticoids in severe exacerbations of COPD. Chest 2001;119:726-30.
71. Decramer M, Gosselink R, Troosters T, Verschueren M, Evers G. Muscle weakness is related to utilization of health care resources in COPD. Eur Respir J 1997;10:417-23.
72. Woolhouse C, Hill S, Stockley R. Symptom resolution assessed using a patient directed diary card during treatment of acute exacerbations of chronic bronchitis. Thorax 2001;56:947-53.
73. Maltais F, Ostinelli J, Bourbeau J, Tonnel A, Jacquemet N, Haddon J. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: A randomized controlled trial. Am J Respir Crit Care Med 2002;165:698-703.
74. Elmes P, Fletcher C, Dutton A. Prophylactic use of oxytetracycline for exacerbations of chronic bronchitis. Br Med J 1957;ii:1272-5.
75. Berry D, Fry J, Hindley C, et al. Exacerbations of chronic bronchitis treatment with oxytetracycline. Lancet 1960;i:137-9.
76. Elmes P, King T, Langlands J, et al. Value of ampicillin in the hospital treatment of exacerbations of chronic bronchitis. Br Med J 1965;5467:904-8.
77. Peterson E, Esmann V, Honcke P, Munkner C. A controlled study of the effect of treatment on chronic bronchitis: An evaluation using pulmonary function tests. Acta Med Scand 1967;182:293-305.
78. Pines A, Raafat H, Greenfield J, Linsell W, Solari M. Antibiotic regimens in moderately ill patients with purulent exacerbations of chronic bronchitis. Br J Dis Chest 1972;66:107-15.
79. Nicotra MB, Rivera M, Awe RJ. Antibiotic therapy of acute exacerbations of chronic bronchitis. A controlled study using tetracycline. Ann Intern Med 1982;97:18-21.
80. Allegre L, Grasi E, Pozzi E. Puolo degli antibiotici nel trattamento delle riacutizza della bronchite cronica. Ital J Chest Dis 1991;45:138-48.
81. Nouira S, Marghli S, Belghith M, Besbes L, Elatrous S, Abroug F. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: A randomized placebo-controlled trial. Lancet 2001;358:2020-35.
82. Sethi S, Paluri R, Grant E, Murphy T. Prediction models for the etiology of acute exacerbations of COPD. Am J Respir Crit Care Med 1999;159:A819. (Abst)
83. Stockley R, O'Brien C, Pye A, Hill S. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000;117:1638-45.
84. Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA 1995;273:957-60.
85. Weiss K, Restieri C, Gauthier R, et al. A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae. Clin Infect Dis 2001;33:517-22.
86. Macfarlane JT, Colville A, Guion A, Macfarlane RM, Rose DH. Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community. Lancet 1993;341:511-4.
87. 1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996;153:1530-5.
88. Ball P, Harris J, Lowson D, Tillotson G, Wilson R. Acute infective exacerbations of chronic bronchitis. QJM 1995;88:61-8.
89. Dewan NA, Rafique S, Kanwar B, et al. Acute exacerbations of COPD: Factors associated with poor treatment outcome. Chest 2000;117:662-71.
90. Miravitlles M, Murio C, Guerrero T, on behalf of the DAFNE study group. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. Eur Respir J 2001;17:928-33.
91. Adams S, Melo J, Luther M, Anzueto A. Antibiotics are associated with lover relapse rates in outpatients with acute exacerbations of COPD. Chest 2000;117:1345-52.
92. Grossman R, Mukherjee J, Vaughan D, et al. A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis. The Canadian Ciprofloxacin Health Economic Study Group. Chest 1998;113:131-41.
93. Kessler R, Faller M, Fourgaut G, Nennevier B, Weitsenblum E. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Crit Care Med 1999;159:158-64.
94. Garcia-Aymerich J, Monso E, Marrales R, et al. Risk factors for a chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med 2001;164:1002-7.
95. Miravitlles M, Guerrero T, Mayordomo C, Sanchez-Agudo L, Nicolau F, Segu JL. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: A multiple logistic regression analysis. The EOLO Study Group. Respiration 2000;67:495-501.
96. Low DE, de Azavedo J, Weiss K, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob Agents Chemother 2002;46:1295-301.
97. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 1995;108(Suppl 2):43S-52S.
98. Eller J, Ede A, Schaberg T, Niederman MS, Mauch H, Lode H. Infective exacerbations of chronic bronchitis: Relation between bacteriologic etiology and lung function. Chest 1998;113:1542-8.
99. Miravitlles M, Espinosa C, Fernandez-Laso E, Martos JA, Maldonado JA, Gallego M. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999;116:40-6.
100. Soler N, Torres A, Ewig S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1498-505.
101. Sportel JH, Koeter GH, van Altena R, Lowenberg A, Boersma WG. Relation between beta-lactamase producing bacteria and patient characteristics in chronic obstructive pulmonary disease (COPD). Thorax 1995;50:249-53.
102. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. Treatment cost of acute exacerbations of chronic bronchitis. Clin Ther 1999;21:576-91.
103. Miravitlles M, Murio C, Guerrero T, Gisbert R. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002;121:1449-55.
104. Gonzales R, Sande M. Uncomplicated acute bronchitis. Ann Intern Med 2000;133:981-91.
105. Macfarlane J, Holmes W, Gard P, Thornhill D, Macfarlane R, Hubbard R. Reducing antibiotic use for acute bronchitis in primary care: Blinded, randomised conrolled trial of patient information leaflet. BMJ 2002;324:91-4.
106. Wilson R, Kubin I, Deppermann K-M, et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999;44:501-13.
107. Shah PM, Maesen FPV, Dolmann A, Vetter N, Fiss E, Wesch R. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbations of chronic bronchitis: Results of a randomized, double-blind study. J Antimicrob Chemother 1999;43:529-39.
108. Langan C, Zuck F, Vogel F, et al. Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1999;44:515-23.
109. Chodosh S. Treatment of acute exacerbations of chronic bronchitis: State of the art. Am J Med 1991;91(Suppl 6A):87S-92S.
110. Chodosh S, Schreurs A, Siami G, et al. Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Clin Infect Dis 1998;27:730-8.
111. Wilson R, Schentag J, Ball P, Mandell L, 068 Study Group. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther 2002;24:639-52.
112. Wilson R, Jones P, Schaberg T, et al. A clinical and outcomes assessment of the management of acute exacerbations of chronic bronchitis (AECB): The Mosaic Study. Twelfth European Respiratory Society Annual Congress, Stockholm, Sweden, September 14 to 18, 2002.
113. Ho P, Tse W, Tsang K, Ng T, Cheng V, Chan R. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: A case-control study. Clin Infect Dis 2001;32:701-7.
114. 1: The Lung Health Study. JAMA 1994;272:1497-505.
115. Higgins M, Enright P, Kronmal R, Schenker M, Anton-Culver H, Lyles M. Smoking and lung function in elderly men and women. The Cardiovascular Health Study. JAMA 1993;269:2741-8.
116. Postma D, Sluiter H. Prognosis of chronic obstructive pulmonary disease: The Dutch experience. Am Rev Respir Dis 1989;140:S100-5.
117. 1, decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: Results from the Lung Health Study. Am J Respir Crit Care Med 2001;164:358-64.
118. Nichol K, Margolis K, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994;331:778-84.
119. Nichol K, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalizations and mortality among elderly patients with chronic lung disease. Ann Intern Med 1999;130:397-403.
120. Butler J, Breiman R, Campbell J, Lipman H, Broome C, Facklam R. Pneomococcal polysaccharide vaccine efficacy: An evaluation of current recommendations. JAMA 1993;270:1826-31.
121. Centre for Disease Control and Prevention. Prevention of pneumococcal disease. MMWR Morb Mortal Wkly Rep 1997;46:1-24.
122. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999;340:1948-53.
123. Vestbo J, Sorensen T, Lange P, Brix A, Torre P. Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 1999;353:1819-23.
124. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-9.
125. McEvoy CE, Niewoehner DE. Adverse effects of corticosteroid therapy for COPD. A critical review. Chest 1997;111:732-43.
126. McEvoy CE, Ensrud KE, Bender E, et al. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:704-9.
127. Schols A, Wesseling G, Kester A, et al. Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids. Eur Respir J 2001;17:337-42.
128. Rice KL, Rubins JB, Lebahn F, et al. Withdrawal of chronic systemic corticosteroids in patients with COPD: A randomized trial. Am J Respir Crit Care Med 2000; 162:174-8.
129. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999;115:957-65.
130. Vincken W, van Noord J, Greefhorst A, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002;19:209-16.
131. Casaburi R, Mahler D, Jones P, Wanner A, San Pedro G, Zu Wallack R. A long-term evaulation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-24.
132. Ruben F. Prophylactic treatment of chronic bronchitis. Semin Respir Infect 1988;3:72-80.
133. Liippo K, Pelliniemi T-T, Lehto H. Trimethoprim prophylaxis of acute exacerbations in chronic obstructive pulmonary disease. Acta Med Scand 1987;21:455-9.
134. Balter MS, Hyland RH, Low D, et al. Recommendations on the management of chronic bronchitis: A practical guide for Canadian physicians. Can Med Assoc J 1994;151(Suppl 10):S7-23.
135. Albert R, Martin T, Lewis S, Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann Intern Med 1980;92:753-8.